| Clinical data | |
|---|---|
| Trade names | Demadex, Tortas, Wator |
| Other names | Torsemide, Torsemide (USANUS) |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a601212 |
| License data | |
| Routes of administration | By mouth,intraveneous |
| Drug class | Loop diuretic |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 80-90% |
| Protein binding | Highly bound (>99%). |
| Metabolism | Liver (80%) |
| Eliminationhalf-life | 3.5 hours;Cirrhosis: 7-8 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.164.924 |
| Chemical and physical data | |
| Formula | C16H20N4O3S |
| Molar mass | 348.42 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Torasemide, also known astorsemide, is a diuretic medication used to treatfluid overload due toheart failure,kidney disease, andliver disease. It is a less preferred treatment for high blood pressure.[1] It is taken by mouth or byinjection into a vein.[1]
Common side effects include headache, increased urination, diarrhea, cough, and dizziness.[1] Other side effects may includehearing loss andlow blood potassium.[1] Torasemide is asulfonamide andloop diuretic.[1] Use is not recommended inpregnancy orbreastfeeding.[2] It works by decreasing the reabsorption ofsodium by thekidneys.[1]
Torasemide was patented in 1974 and came into medical use in 1993.[3] It is on theWorld Health Organization's List of Essential Medicines.[4] It is available as ageneric medication.[2] In 2023, it was the 193rd most commonly prescribed medication in the United States, with more than 2 million prescriptions.[5][6]
It is used to treatfluid overload due toheart failure. It is sometimes used to treathigh blood pressure.[1] Compared with furosemide, torasemide is associated with a lower risk of rehospitalization for heart failure and with improvement in New York Heart Association functional class, reflected by a reduction in NYHA class severity.[7][8][9] In heart failure it may be safer and more effective thanfurosemide.[10][11][12] Long-term outcomes with torasemide may be better than with furosemide in patients with heart failure.[13]
No evidence of torasemide-inducedototoxicity has been demonstrated in humans.[14]
Loop diuretics, including torsemide, may decrease total bodythiamine, particularly in people with poor thiamine intake, and this depletion may worsen heart failure. It is therefore reasonable to either also give thiamine supplements or to check blood thiamine levels in those being treated with chronic loop diuretics.[15]
Compared with other loop diuretics, torasemide has a more prolongeddiuretic effect than equipotent doses offurosemide and relatively decreasedpotassium loss.[16]
This sectiondoes notcite anysources. Please helpimprove this section byadding citations to reliable sources. Unsourced material may be challenged andremoved.(February 2024) (Learn how and when to remove this message) |
Torasemide is the recommended name of the drug (rINN) according to the (INN), which is the drug naming system coordinated by theWorld Health Organization. Torsemide is the official name of the drug according to the (USAN), which is the drug naming system coordinated by the USAN Council, which is co-sponsored by the American Medical Association (AMA), the United States Pharmacopeial Convention (USP), and the American Pharmacists Association (APhA).
In May 2024, the US FDA conditionally approved the first torsemide animal medication for dogs. UpCard-CA1 (torsemide oral solution) was conditionally approved for use with concurrent therapy withpimobendan,spironolactone, and anangiotensin-converting enzyme (ACE) inhibitor for the management ofpulmonary edema (fluid build-up in lungs) in dogs with congestive heart failure caused bymyxomatous mitral valve disease (MMVD).[17][18]